Genentech : Phase III Studies Of Gantenerumab In Early Alzheimer's Disease Fails To Meet Main Goal
14/11 07:29
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said Monday that phase III GRADUATE studies, which evaluated gantenerumab in people with early Alzheimer's disease, did not meet their primary endpoints of slowing clinical decline. Gantenerumab was well tolerated includ...